Visualization analysis of SGLT2 inhibitors in the treatment of heart failure based on CiteSpace
Journal Title: Journal of Air Force Medical University - Year 2023, Vol 44, Issue 10
Abstract
Objective To visually analyze the number of papers, authors, research institutions and keywords related to sodium-glucose cotransporter 2 (SGLT2) inhibitors in the treatment of heart failure ( HF) by using CiteSpace, and to explore the development status, research hotspots and research frontiers of SGLT2 inhibitors in the treatment of HF. Methods The core collection database of Web of Science was used as the retrieval source, the bibliometric software CiteSpace V based on Java platform was used to process and analyze the included papers, and the relevant knowledge graph was obtained. Results Since the publication of Web of Science database in 1997, the English papers on SGLT2 inhibitors in the treatment of HF were first published in 2012, and the number of papers in this field showed an increasing trend from 2012 to 2021, indicating that this field was still in the development stage. A total of 1 051 papers were included in this study, including 471 papers from the United States, the country with the largest number of papers in this field. The research institution with the largest number of papers was the University of Toronto in Canada, and the cooperation among the research institutions was less and scattered. The research hotspots in this field were mainly the benefit of SGLT2 inhibitors in the treatment of diabetes mellitus, cardiovascular diseases and chronic kidney disease and their mechanism of action. Conclusion One of the current research hotspots in this field is the benefit of SGLT2 inhibitors in the treatment of HF, which has been gradually expanded to the benefit of SGLT2 inhibitors in the treatment of other cardiovascular diseases such as atrial fibrillation and myocardial infarction, and chronic kidney disease. These drugs can improve the prognosis of diabetic patients, reduce the mortality of HF patients, reduce the occurrence of renal failure in diabetic patients, and play a certain role in lowering blood pressure by optimizing blood volume. At present, only SGLT2 inhibitors have the above multiple effects. Therefore, it is speculated that SGLT2 inhibitors have broad clinical application prospects.
Authors and Affiliations
ZHANG Jun, LU Jianqi, PAN Chaoxin, LI Qianyu, WEN Zhihao
Keywords
Related Articles
- EP ID EP723870
- DOI -
- Views 39
- Downloads 0
Dynamic functional connectivety study of rapid anti-depression and suicidal ideation relief with SAINT
Objective To analyze the dynamic functional connectivity ( DFC) characteristics of brain networks in patients with major depressive disorder ( MDD ) treated by Stanford Accelerated Intelligent Neuromodulation Therapy (...
Anesthesiology expands comfortable medical services: contributions and challenges
Anesthesiology was born with the need of comfortable medical treatment, and the realization of medical comfort has always been the most fundamental historical mission of anesthesiology. In recent years, the field of an...
Relationship between inflammatory indexes in peripheral blood of COPD patients at stable stage and comprehensive assessment of disease severity
Objective To observe the expression of cytokines and inflammatory indexes in peripheral blood of patients with chronic obstructive pulmonary disease ( COPD) in different groups at stable stage, and analyze their correla...
Investigation of chronic prostatitis-like symptoms and related risk factors among soldiers at high altitude
Objective To investigate the incidence and related risk factors of chronic prostatitis-like symptoms (CPLS) in soldiers at high altitude. Methods A cluster sampling survey was conducted among soldiers at grass-roots lev...
Research progress in white matter genetic imaging biomarkers for screening people at high risk for schizophrenia
The global disease burden of schizophrenia is very heavy. The epidemiological survey of mental disorders in the PLA shows that schizophrenia has the highest prevalence rate, about 0. 16% , and is the most common cause o...